Ulcerative colitis. ulcerative colitis
Conditions
Interventions
Intervention 1: Oral curcumin as 80 mg nanomicelle capsule, three capsules per day in three divided doses before meals for 4 weeks plus standard treatment for each patient as needed which at least in
Treatment - Drugs
Placebo
Oral curcumin as 80 mg nanomicelle capsule, three capsules per day in three divided doses before meals for 4 weeks plus standard treatment for each patient as needed which at least includes oral mesa
Oral placebo capsule, three capsules per day in three divided doses before meals for 4 weeks plus standard treatment for each patient as needed which at least includes oral mesalamine tablets 500 mg,
Sponsors
Deputy of Research and Technology, Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients 18-80 years old with mild to moderate ulcerative colitis based on Simple Clinical Colitis Activity Index Exclusion criteria: hospital admission; significant comorbidities including liver or kidney diseases; pregnancy; lactating women; significant side effects during the intervention
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of ulcerative colitis. Timepoint: Before the intervention, two weeks and four weeks after the intervention onset. Method of measurement: Based on Simple Clinical Colitis Activity Index. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: Two weeks and four weeks after the intervention onset and also any time patient reports during the intervention. Method of measurement: Interviews with patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadali Mahdiabadi
Iran University of Medical Sciences
Outcome results
None listed